Comments on vaccines, August 1987.
Because of latency and infectious recurrences, eradication of herpes simplex and herpes zoster from the world by vaccines is likely to be much more difficult to accomplish than eradication of smallpox. For some time we may have to settle for control of these diseases rather than their eradication. The live, attenuated varicella vaccine protects immunocompromised and normal persons against clinical chickenpox but it does not completely prevent subsequent infection with natural chickenpox virus or latency. With herpes simplex vaccines we may have to be satisfied with amelioration or control of clinical infections and diminution of latency and recurrent disease. Varicella zoster immune globulin plays a useful role in attenuation of varicella in immunocompromised or special-risk persons exposed to varicella zoster virus. Passive immunization for herpes simplex (herpes simplex immune globulin or other antibody preparations) has been studied very little. Maybe passive immunization will have a place in future therapies, especially for serious herpes simplex virus infections in immunocompromised hosts.
Wheeler
C E
CE
Department of Dermatology, University of North Carolina School of Medicine, North Carolina Memorial Hospital, Chapel Hill 27514.
D000818:Animals; D002644:Chickenpox / Q000517:prevention & control*; D006561:Herpes Simplex / Q000517:prevention & control*; D006562:Herpes Zoster / Q000517:prevention & control*; D006801:Humans; D012008:Recurrence; D014765:Viral Vaccines
D014765:Viral Vaccines